Genentech Medicine Avastin Plus Chemotherapy Improved Survival in Women with Advanced Cervical Cancer, Compared to Chemotherapy Alone

Genentech Announces Final Phase III Study Results of Avastin Plus Radiotherapy and Chemotherapy in People with an Aggressive Form of Brain Cancer

Genentechs Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer

FDA Approval: Personalized Medicine for a Specific Type of Metastatic Non-Small Cell Lung Cancer (NSCLC) as Detected by an FDA-Approved Test

On May 14, 2013, the FDA approved a personalized medicine for people newly diagnosed with a genetically distinct type of metastatic NSCLC.

View information and materials

FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer

Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO

FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer

Celebrating the 60th Anniversary of Watson & Crick's Discovery

Genentech built an iPad app that turns a primary genetic concept into a maddeningly addictive mobile game.

View information and materials

FDA Approves Actemra® For Children Living with A Rare Form of Arthritis

Phase III Results Showed omalizumab Significantly Reduced Disease Severity in Patients with a Chronic form of Hives who Failed Standard Therapy

FDA Approves New Genentech Medicine for HER2-Positive Metastatic Breast Cancer

On February 22^nd, 2013, the FDA approved a new personalized Genentech medicine for people with an aggressive form of breast cancer.

View information and materials

FDA Approves Genentech’s Kadcyla (ado-trastuzumab emtansine), the First Antibody-Drug Conjugate for Treating HER2-Positive Metastatic Breast Cancer

Obinutuzumab (GA101) Significantly Improved Progression-Free Survival in People with Chronic Lymphocytic Leukemia (CLL)

FDA Approves New Use of Genentech Medicine for People with Metastatic Colorectal Cancer

On January 23, 2013, a Genentech medicine received FDA approval for a new use in metastatic colorectal cancer.

View information and materials

FDA Approves New Use of Avastin Plus Chemotherapy For People With Metastatic Colorectal Cancer

Genentech Announces FDA Approval Of Tamiflu For The Treatment Of Influenza In Infants

Genentechs Perjeta Significantly Extends Survival in People With HER2-Positive Metastatic Breast Cancer

Genentech Study Showed That Avastin Helped People with Newly Diagnosed Glioblastoma Live Longer without Their Disease Worsening When Added to Radiation and Chemotherapy

ADACTA Study Showed ACTEMRA Improved Signs and Symptoms of Rheumatoid Arthritis Significantly More Than Adalimumab as a Single-Agent Therapy

FDA Grants Genentech's Trastuzumab Emtansine (T-DM1) Priority Review for HER2-Positive Metastatic Breast Cancer

FDA Approves Expanded Use of Genentech Medicine in Rheumatoid Arthritis

On October 12, 2012, a Genentech medicine received approval from the FDA to expand its indication for Rheumatoid Arthritis.

View information and materials

Genentech's Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer

FDA Approves Expanded Indication for ACTEMRA^® in Rheumatoid Arthritis

gRide Program Achieves Milestone

gRide, Genentech's employee commuting program, has now saved 100 million miles of driving since the program's inception began in late 2006. The program began as a way to reduce the number of vehicles that travel to and park on the South San Francisco campus, and since has had significant impact on Genentech's sustainability goals and employee quality of life.

View information and materials

Genentech Medicine Approved for Diabetic Macular Edema (DME)

gOn August 10, 2012, a Genentech medicine was approved by the FDA for diabetic macular edema (DME).

View information and materials

Genentech Gives Back Week 2012

Genentech Gives Back Week (June 11 - 6, 2012) is a unique opportunity for Genentech employees to support the communities where we live and work.

View information and materials